

Robert Bissonnette

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/443932/robert-bissonnette-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115
papers

4,302
citations

38
h-index

62
g-index

119
ext. papers

5,362
ext. citations

3.3
avg, IF

5.34
L-index

#	Paper	IF	Citations
115	A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.. <i>American Journal of Clinical Dermatology</i> , 2022 , 1	7.1	2
114	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. <i>Dermatology and Therapy</i> , 2021 , 11, 2179-2193	4.93	3
113	Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. <i>Dermatology and Therapy</i> , 2021 , 11, 571-585	4	18
112	Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1174-1190.e1	11.5	32
111	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 3107-3121	9.3	6
110	Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. <i>Drug Safety</i> , 2021 , 44, 699-709	5.1	0
109	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1707-1718.e9	4.3	16
108	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 62-70	4.5	27
107	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 476-485	4.6	35
106	Inflammatory Skin Disorders: Monocyte-Derived Cells Take Center Stage. <i>Frontiers in Immunology</i> , 2021 , 12, 691806	8.4	2
105	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020 , 183, 242-255	4	137
104	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 839-846	4.5	30
103	Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1015-1025.e4	4.3	5
102	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020 , 10, e039928	3	0
101	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e21-e24	4.6	2
100	IL-4R β Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 191-202.e7	4.3	57
99	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 1011-1024	11.5	54

98	Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 5S-10S	1.6	3
97	Crisaborole and atopic dermatitis skin biomarkers: An inpatient randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 1274-1289	11.5	40
96	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019 , 46, 751-754	4.1	14
95	The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. <i>British Journal of Dermatology</i> , 2019 , 181, 733-742	4	63
94	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , 2019 , 181, 88-95	4	42
93	Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 714-721	4.5	35
92	Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2228-2232.e10	4.3	9
91	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019 , 2, 149-152 ^{0.5}		2
90	Ultraviolet B-induced immunosuppression is not associated with receptor activator of nuclear factor kappa B ligand upregulation in human skin. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019 , 35, 47-50	2.4	
89	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 155-172	11.5	246
88	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 50-74	1.6	58
87	JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , 2018 , 178, 321	4	4
86	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1507-1514	4.6	119
85	Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 524-531	2.3	14
84	Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 403-410	4.6	22
83	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 844-852	4	59
82	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 30S-35S	1.6	5
81	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 10S-16S	1.6	13

80	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 3S-5S	1.6	3
79	Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. <i>British Journal of Dermatology</i> , 2018 , 179, 853-862	4	37
78	Increase in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 800-802	4	8
77	TNF- α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1638-1645	4.3	56
76	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. <i>British Journal of Dermatology</i> , 2017 , 177, 1033-1042	4	38
75	Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 755-756	4.5	1
74	Response to Hjuler et al. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2237-2238	4.3	
73	Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 33-39	4.5	21
72	Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy. <i>British Journal of Dermatology</i> , 2017 , 177, 267-270	4	6
71	Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. <i>Journal of Dermatological Science</i> , 2017 , 85, 20-26	4.3	23
70	The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 793-799	2.2	9
69	Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 1002-1013	2.2	14
68	Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. <i>British Journal of Dermatology</i> , 2016 , 175, 902-911	4	263
67	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 332-8	2.8	48
66	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 851-61.e4	4.5	59
65	Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. <i>PLoS ONE</i> , 2016 , 11, e0155215	3.7	26
64	Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1115-9	4.6	21
63	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016 , 16, 15	2.1	51

62	Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 99-105	4.5	54
61	Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 612-618.e6	4.5	37
60	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015 , 172, 1395-406	4	106
59	Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1576-81	4.6	3
58	Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 351-9.e1	11.5	120
57	Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 373-5	2.8	12
56	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015 , 42, 1767-80	4.1	88
55	Changes in serum free testosterone, sleep patterns, and 5-alpha-reductase type I activity influence changes in sebum excretion in female subjects. <i>Skin Research and Technology</i> , 2015 , 21, 47-53	1.9	7
54	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). <i>British Journal of Dermatology</i> , 2015 , 173, 777-87	4	62
53	Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 57-60	2.8	23
52	Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1298-305	4.6	56
51	A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013 , 169, 137-45	4	156
50	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1535-45	4.6	137
49	Effects of the tumor necrosis factor- α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. <i>Circulation: Cardiovascular Imaging</i> , 2013 , 6, 83-90	3.9	61
48	Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013 , 17, 398-403	1.6	18
47	Influence of the quantity of sunscreen applied on the ability to protect against ultraviolet-induced polymorphous light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012 , 28, 240-3	2.4	11
46	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. <i>Journal of Dermatological Treatment</i> , 2012 , 23, 261-7	2.8	40
45	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, e33-45	4.5	69

44	Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 1386-7	4.5	4
43	Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. <i>British Journal of Dermatology</i> , 2012 , 166, 853-60	4	48
42	Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1516-21	4.6	28
41	Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. <i>Journal of Cosmetic Dermatology</i> , 2011 , 10, 174-8	2.5	21
40	Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1402-8	4.6	44
39	Chemoprevention of Skin Cancer with Photodynamic Therapy 2011 , 139-147		1
38	Treatment of acne with photodynamic therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2011 , 146, 445-56	0.8	4
37	Redefining treatment options in chronic hand eczema (CHE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24 Suppl 3, 1-20	4.6	36
36	A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. <i>Journal of Cosmetic Dermatology</i> , 2010 , 9, 16-21	2.5	42
35	Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. <i>British Journal of Dermatology</i> , 2010 , 162, 420-6	4	68
34	Canadian hand dermatitis management guidelines. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010 , 14, 267-84	1.6	38
33	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 228-34 ⁵		39
32	Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. <i>Archives of Dermatology</i> , 2010 , 146, 446-9		28
31	Photodynamic therapy with methylaminolevulinate 80 mg/g without occlusion improves acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2010 , 9, 1347-52	2.2	22
30	The AWARE study: methodology and baseline characteristics. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S113-21	1.6	5
29	Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S131-8	1.6	4
28	Efficacy outcomes in patients using alefacept in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S122-30	1.6	2
27	Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 2, S67-76	1.6	11

26	Randomized study comparing the efficacy and tolerance of a lipophilic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. <i>Journal of Cosmetic Dermatology</i> , 2009 , 8, 19-23	2.5	23
25	Protection afforded by sunscreens containing inorganic sunscreens agents against blue light sensitivity induced by aminolevulinic acid. <i>Dermatologic Surgery</i> , 2008 , 34, 1469-76	1.7	14
24	Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. <i>British Journal of Dermatology</i> , 2008 , 158, 808-17	4	272
23	Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. <i>Lancet, The</i> , 2008 , 371, 1337-42	4.0	67
22	Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008 , 12, 230-4	1.6	32
21	Etanercept in the treatment of palmoplantar pustulosis. <i>Journal of Drugs in Dermatology</i> , 2008 , 7, 940-6	2.2	40
20	Chemopreventative thoughts for photodynamic therapy. <i>Dermatologic Clinics</i> , 2007 , 25, 95-100	4.2	8
19	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 472-8	4.5	47
18	Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. <i>British Journal of Dermatology</i> , 2006 , 154, 740-2	4	27
17	Irradiance and light dose influence histological localization of photodamage induced by photodynamic therapy with aminolaevulinic acid. <i>British Journal of Dermatology</i> , 2004 , 151, 653-5	4	9
16	Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 131-9	1.6	13
15	Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-37	1.6	23
14	Multiple Large-Surface Photodynamic Therapy Sessions with Topical or Systemic Aminolevulinic Acid and Blue Light in UV-Exposed Hairless Mice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 131-139	1.6	23
13	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-337	1.6	38
12	Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice. <i>Archives of Dermatological Research</i> , 2002 , 294, 237-42	3.3	44
11	002Multiple exposures to blue light does not improve psoriasis in patients with elevated endogenous levels of protoporphyrin IX. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002 , 18, 104-104	2.4	
10	Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2002 , 67, 11-7	6.7	31
9	Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 77-83	4.3	52

8	Prevention of polymorphous light eruption and solar urticaria. <i>Skin Therapy Letter</i> , 2002 , 7, 3-5	1.8	
7	Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet-induced skin tumours in mice. <i>British Journal of Dermatology</i> , 2001 , 144, 1207-14	4	32
6	Photodynamic therapy with 5-aminolevulinic acid induces apoptosis and caspase activation in malignant T cells. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001 , 5, 8-13	1.6	31
5	Comparison of UVA protection afforded by high sun protection factor sunscreens. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 1036-8	4.5	19
4	Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp. <i>Archives of Dermatology</i> , 1999 , 135, 1421-2		11
3	Current status of photodynamic therapy in dermatology. <i>Dermatologic Clinics</i> , 1997 , 15, 507-19	4.2	58
2	Characterization of 57 kDa statin as a true marker for growth arrest in tissue by its disappearance from regenerating liver. <i>Journal of Cellular Physiology</i> , 1994 , 158, 277-84	7	4
1	Drug-induced toxic pustuloderma. <i>International Journal of Dermatology</i> , 1992 , 31, 172-4	1.7	18